On March 29, 2023 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, reported the company will provide a Corporate Update on Monday, April 17, 2023, at 8:00 am Eastern Time. This event replaces the webcast and call originally scheduled for March 31, 2023 (Press release, Chemomab, MAR 29, 2023, View Source,-2023 [SID1234629493]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the event, Chemomab’s management team will review recent corporate developments and conduct a live question-and-answer session.

A replay will be available on Chemomab’s website for 90 days at www.chemomab.com.

Live Webcast and Conference Call at 8:00 am Eastern Time, Monday, April 17, 2023

Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.

Conference Call Access via Telephone

US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference Passcode: #13735392
Or click on Call me for instant telephone access to the event

Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.

On March 29, 2023 bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent commercial and operational progress, and regulatory updates (Press release, bluebird bio, MAR 29, 2023, View Source [SID1234629492]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Following two milestone FDA approvals in 2022, bluebird is now emerging as a commercial gene therapy leader, fueled by strong momentum and uptake for both ZYNTEGLO and SKYSONA across patients, payers and providers," said Andrew Obenshain, chief executive officer, bluebird bio. "We also remain laser focused on our lovo-cel BLA for sickle cell disease. Following feedback from the FDA in February, bluebird submitted additional information related to CMC comparability analyses to the FDA in early March; we anticipate a response from the Agency within a matter of weeks. Lovo-cel is the most deeply studied gene therapy in development for sickle cell disease, with more than 50 patients treated and multiple patients followed for more than six years. We remain extremely confident in the quality of our BLA submission. Most importantly, we know that patients and their families are waiting, and we will move quickly to expedite our BLA submission, pending alignment with FDA on product comparability."

RECENT HIGHLIGHTS

lovo-cel (lovotibeglogene autotemcel) BLA Submission Progressing

•In early March, the Company responded to feedback from the FDA on vector and drug product analytical comparability evaluations completed in December 2022; bluebird expects a response from the FDA within a matter of weeks and will move quickly to expedite its BLA submission, pending alignment with FDA on product comparability.

•The Company plans to request priority review for patients 12 and older with a history of vaso-occlusive events. If approved, bluebird continues to anticipate a commercial launch in early 2024.

Momentum Continues in ZYNTEGLO (betibeglogene autotemcel) Commercial Launch

•bluebird has made significant progress in the launch of ZYNTEGLO, with five patient starts (cell collections) for patients with beta-thalassemia to date.

•As launch continues to progress, bluebird is advancing plans to expand manufacturing capacity to meet growing projected demand.

image_0.jpg

•On average, prior authorization for the therapy remains at just two weeks, a strong indicator of payer acceptance for ZYNTEGLO; to date, there have continued to be zero ultimate denials for payer coverage.

•bluebird’s qualified treatment center (QTC) network continues to scale as planned with 12 activated QTCs (defined as a signed master service agreement or MSA) and approximately 30 QTCs in the on-boarding or MSA negotiation phase; the Company remains on track to scale to 40-50 centers by the end of 2023.

•As previously announced, during ZYNTEGLO’s 2023 launch year, the Company expects to report key metrics, including the number of patient starts. bluebird does not expect to provide ZYNTEGLO revenue projections for 2023.

SKYSONA (elivaldogene autotemcel) Commercial Launch Continues on Track

•Cell collection has been completed for two patients to be treated with SKYSONA and the first commercial infusion has been completed.

•Since approval, bluebird has activated three QTCs to treat patients with cerebral adrenoleukodystrophy (CALD).

Richard Paulson, MBA appointed to bluebird bio Board of Directors

•On March 24, 2023, Richard Paulson was appointed to bluebird bio’s Board of Directors, effective April 3, 2023. Mr. Paulson is currently President and Chief Executive Officer of Karyopharm Therapeutics. He was previously Executive Vice President and Chief Executive Officer of Ipsen North America, where he focused on innovative therapies and specialty care for oncology, neuroscience and rare diseases. An experienced global biotech and pharmaceutical leader, Mr. Paulson has served in a number of leadership roles across multiple continents, including general management, marketing, sales and market access.
UPCOMING ANTICIPATED MILESTONES
LOVO-CEL
•BLA submission anticipated following response from FDA on analytical comparability data in the coming weeks.
•The Company continues to anticipate commercial launch in early 2024, if approved.

ZYNTEGLO
•The Company is on track to scale to 40-50 centers by the end of 2023.

SKYSONA
•The Company remains on track for 5-10 patient starts this year as previously guided.

FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

•Cash Position: The Company’s cash and cash equivalents, marketable securities and restricted cash balance was approximately $227 million, as of December 31, 2022. As bluebird bio

launches two first-in-class gene therapies and readies its third investigational gene therapy for SCD for the commercial setting, full-year 2023 cash burn is expected to be in the range of $270-$300 million, as previously guided. Based on current operating plans, bluebird expects its cash, cash equivalents, restricted cash and marketable securities, including the net proceeds from the sale of its second priority review voucher (PRV) of $93 million and net proceeds of $131 million from its public offering in January, will be sufficient to meet bluebird’s planned operating expenses and capital expenditure requirements into the fourth quarter of 2024. This runway includes approximately $45 million of restricted cash, which is currently unavailable for use. Please see our Annual Report filed on Form 10-K for further information regarding our cash runway guidance and other financial results.

•Revenues: Total revenue was $0.06 million for the three months ended December 31, 2022, compared to $1.6 million for the three months ended December 31, 2021. Total revenue was $3.6 million for the twelve months ended December 31, 2022, compared to $3.7 million for the twelve months ended December 31, 2021. The Company anticipates reporting commercial revenue in its Q1 2023 financial statement, as previously guided.

•R&D Expenses: Research and development expenses from continuing operations were $45.9 million for the three months ended December 31, 2022, compared to $79.4 million for the three months ended December 31, 2021. Research and development expenses from continuing operations were $240.8 million for the twelve months ended December 31, 2022, compared to $320.0 million for the twelve months ended December 31, 2021. The decrease in both periods were primarily due to decreased employee compensation, benefits, other head-count related expenses, information technology and facility-related costs, clinical trial costs, and laboratory costs.

•SG&A Expenses: Selling, general and administrative expenses from continuing operations were $30.7 million for the three months ended December 31, 2022, compared to $53.2 million for the three months ended December 31, 2021. Selling, general and administrative expenses from continuing operations were $136.9 million for the twelve months ended December 31, 2022, compared to $210.0 million for the twelve months ended December 31, 2021. The decrease in both periods were primarily due to decreased employee compensation, benefit, and other head-count related expenses and decreased commercial readiness activities due to the Company’s decision to focus its efforts on the U.S. market.

•Gain from sale of priority review voucher: The increase in gain from sale of priority review voucher, net was related to the sale of a priority review voucher for $102 million in the fourth quarter of 2022.

•Net Income/Loss: Net income from continuing operations was $32.2 million for the three months ended December 31, 2022, compared to a loss of $132.3 million for the three months ended December 31, 2021. Net loss from continuing operations was $266.6 million for the twelve months ended December 31, 2022, compared to $562.6 million for the twelve months ended December 31, 2021.

CONFERENCE CALL DETAILS
bluebird will hold a conference call to discuss fourth quarter and full year 2022 financial results and operational progress on Wednesday, March 29 at 8:00 am ET.

To access the call via telephone please follow this link https://register.vevent.com/register/BI0a0b3cf9c17a46cbbabcc02f50c3f12e to register online and receive a dial in number and unique PIN to access the live conference call.

The live webcast of the call may be accessed by visiting the "Events & Presentations" page within the Investors & Media section of the bluebird website at View Source A replay of the webcast will be available on the bluebird website for 90 days following the event.

On March 29, 2023 bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent commercial and operational progress, and regulatory updates (Press release, bluebird bio, MAR 29, 2023, View Source [SID1234629491]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Following two milestone FDA approvals in 2022, bluebird is now emerging as a commercial gene therapy leader, fueled by strong momentum and uptake for both ZYNTEGLO and SKYSONA across patients, payers and providers," said Andrew Obenshain, chief executive officer, bluebird bio. "We also remain laser focused on our lovo-cel BLA for sickle cell disease. Following feedback from the FDA in February, bluebird submitted additional information related to CMC comparability analyses to the FDA in early March; we anticipate a response from the Agency within a matter of weeks. Lovo-cel is the most deeply studied gene therapy in development for sickle cell disease, with more than 50 patients treated and multiple patients followed for more than six years. We remain extremely confident in the quality of our BLA submission. Most importantly, we know that patients and their families are waiting, and we will move quickly to expedite our BLA submission, pending alignment with FDA on product comparability."

RECENT HIGHLIGHTS

lovo-cel (lovotibeglogene autotemcel) BLA Submission Progressing

In early March, the Company responded to feedback from the FDA on vector and drug product analytical comparability evaluations completed in December 2022; bluebird expects a response from the FDA within a matter of weeks and will move quickly to expedite its BLA submission, pending alignment with FDA on product comparability.
The Company plans to request priority review for patients 12 and older with a history of vaso-occlusive events. If approved, bluebird continues to anticipate a commercial launch in early 2024.
Momentum Continues in ZYNTEGLO (betibeglogene autotemcel) Commercial Launch

bluebird has made significant progress in the launch of ZYNTEGLO, with five patient starts (cell collections) for patients with beta-thalassemia to date.
As launch continues to progress, bluebird is advancing plans to expand manufacturing capacity to meet growing projected demand.
On average, prior authorization for the therapy remains at just two weeks, a strong indicator of payer acceptance for ZYNTEGLO; to date, there have continued to be zero ultimate denials for payer coverage.
bluebird’s qualified treatment center (QTC) network continues to scale as planned with 12 activated QTCs (defined as a signed master service agreement or MSA) and approximately 30 QTCs in the on-boarding or MSA negotiation phase; the Company remains on track to scale to 40-50 centers by the end of 2023.
As previously announced, during ZYNTEGLO’s 2023 launch year, the Company expects to report key metrics, including the number of patient starts. bluebird does not expect to provide ZYNTEGLO revenue projections for 2023.
SKYSONA (elivaldogene autotemcel) Commercial Launch Continues on Track

Cell collection has been completed for two patients to be treated with SKYSONA and the first commercial infusion has been completed.
Since approval, bluebird has activated three QTCs to treat patients with cerebral adrenoleukodystrophy (CALD).
Richard Paulson, MBA appointed to bluebird bio Board of Directors

On March 24, 2023, Richard Paulson was appointed to bluebird bio’s Board of Directors, effective April 3, 2023. Mr. Paulson is currently President and Chief Executive Officer of Karyopharm Therapeutics. He was previously Executive Vice President and Chief Executive Officer of Ipsen North America, where he focused on innovative therapies and specialty care for oncology, neuroscience and rare diseases. An experienced global biotech and pharmaceutical leader, Mr. Paulson has served in a number of leadership roles across multiple continents, including general management, marketing, sales and market access.
UPCOMING ANTICIPATED MILESTONES

LOVO-CEL

BLA submission anticipated following response from FDA on analytical comparability data in the coming weeks.
The Company continues to anticipate commercial launch in early 2024, if approved.
ZYNTEGLO

The Company is on track to scale to 40-50 centers by the end of 2023.
SKYSONA

The Company remains on track for 5-10 patient starts this year as previously guided.
FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

Cash Position: The Company’s cash and cash equivalents, marketable securities and restricted cash balance was approximately $227 million, as of December 31, 2022. As bluebird bio launches two first-in-class gene therapies and readies its third investigational gene therapy for SCD for the commercial setting, full-year 2023 cash burn is expected to be in the range of $270-$300 million, as previously guided. Based on current operating plans, bluebird expects its cash, cash equivalents, restricted cash and marketable securities, including the net proceeds from the sale of its second priority review voucher (PRV) of $93 million and net proceeds of $131 million from its public offering in January, will be sufficient to meet bluebird’s planned operating expenses and capital expenditure requirements into the fourth quarter of 2024. This runway includes approximately $45 million of restricted cash, which is currently unavailable for use. Please see our Annual Report filed on Form 10-K for further information regarding our cash runway guidance and other financial results.
Revenues: Total revenue was $0.06 million for the three months ended December 31, 2022, compared to $1.6 million for the three months ended December 31, 2021. Total revenue was $3.6 million for the twelve months ended December 31, 2022, compared to $3.7 million for the twelve months ended December 31, 2021. The Company anticipates reporting commercial revenue in its Q1 2023 financial statement, as previously guided.
R&D Expenses: Research and development expenses from continuing operations were $45.9 million for the three months ended December 31, 2022, compared to $79.4 million for the three months ended December 31, 2021. Research and development expenses from continuing operations were $240.8 million for the twelve months ended December 31, 2022, compared to $320.0 million for the twelve months ended December 31, 2021. The decrease in both periods were primarily due to decreased employee compensation, benefits, other head-count related expenses, information technology and facility-related costs, clinical trial costs, and laboratory costs.
SG&A Expenses: Selling, general and administrative expenses from continuing operations were $30.7 million for the three months ended December 31, 2022, compared to $53.2 million for the three months ended December 31, 2021. Selling, general and administrative expenses from continuing operations were $136.9 million for the twelve months ended December 31, 2022, compared to $210.0 million for the twelve months ended December 31, 2021. The decrease in both periods were primarily due to decreased employee compensation, benefit, and other head-count related expenses and decreased commercial readiness activities due to the Company’s decision to focus its efforts on the U.S. market.
Gain from sale of priority review voucher: The increase in gain from sale of priority review voucher, net was related to the sale of a priority review voucher for $102 million in the fourth quarter of 2022.
Net Income/Loss: Net income from continuing operations was $32.2 million for the three months ended December 31, 2022, compared to a loss of $132.3 million for the three months ended December 31, 2021. Net loss from continuing operations was $266.6 million for the twelve months ended December 31, 2022, compared to $562.6 million for the twelve months ended December 31, 2021.
CONFERENCE CALL DETAILS

bluebird will hold a conference call to discuss fourth quarter and full year 2022 financial results and operational progress on Wednesday, March 29 at 8:00 am ET.

To access the call via telephone please follow this link https://register.vevent.com/register/BI0a0b3cf9c17a46cbbabcc02f50c3f12e to register online and receive a dial in number and unique PIN to access the live conference call.

The live webcast of the call may be accessed by visiting the "Events & Presentations" page within the Investors & Media section of the bluebird website at View Source A replay of the webcast will be available on the bluebird website for 90 days following the event.

On March 29, 2023 Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported that it has commenced an underwritten public offering of $125.0 million of shares of its common stock (Press release, Biomea Fusion, MAR 29, 2023, View Source [SID1234629490]). All of the shares of the common stock in the proposed offering are being offered by Biomea. In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan and Citigroup are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. and Barclays are also acting as joint book-running managers for the proposed offering.

The securities are being offered by Biomea pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and may be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected]; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at [email protected] ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, or by emailing [email protected]; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On March 29, 2023 Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided an overview of recent developments (Press release, Atreca, MAR 29, 2023, View Source [SID1234629489]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Last year was a productive time for Atreca, with advances made in our discovery platform, preclinical programs, and ATRC-101," said John Orwin, Chief Executive Officer of Atreca. "Today we are pleased to report additional data from our ongoing Phase 1b trial, which show that ATRC-101 continues to be well tolerated, and that longer progression free survival was observed in patients with high target expression in this early trial. Patient enrollment based on target expression is ongoing in both the monotherapy and combination cohorts of the study and we expect to report additional data and go/no-go decisions for Phase 2 development toward the end of this year."

"We believe these data further validate the ability of our proprietary platform to identify potentially valuable therapeutic antibodies against novel targets in oncology," Mr. Orwin added. "Continued investments in our discovery platform have accelerated the growth of our preclinical pipeline, and we look forward to nominating our next two clinical candidates later this year."

ATRC-101 Update

The Phase 1b trial is a first-in-human, open-label study of ATRC-101 as monotherapy and in combination with pembrolizumab in patients with select solid tumor cancers. Once every 3-week (Q3W) and once every 2-week (Q2W) schedules have been evaluated at dose levels up to 30 mg/kg with no dose-limiting toxicities observed. Enrollment is ongoing at the 30 mg/kg ATRC-101 dose level in both the Q3W monotherapy and combination arms of the trial, with participants selected based on target expression.
As of the data cut-off date of February 17, 2023, a total of 71 participants had been dosed in the trial and evaluated for safety, with 62 participants receiving either the 3, 10 or 30 mg/kg dose including 42 participants treated in the Q3W monotherapy arm, 11 in the Q2W monotherapy arm, and 9 in the combination arm. Participants enrolled in the study had received a median of five prior lines of treatment. All participants in the combination arm had experienced an unsatisfactory tumor response or progression following prior anti-PD-1 or anti-PD-L1 therapy.

ATRC-101 has been generally well-tolerated. For the 71 participants enrolled, most of the reported adverse events were grade ≤ 2. Only two grade 3 AEs were considered potentially treatment-related, which were one instance each of headache and a small intestinal obstruction. The most common treatment-related AEs were fatigue (n=17, 24%) and pain (n=14, 20%), with no serious adverse events determined to be related to treatment with ATRC-101.
The Company continued to observe that high target expression (as defined by an H-score ≥50) discriminates for anti-tumor activity in the 3, 10 and 30 mg/kg dose cohorts. Among the 17 participants with a high target expression at screening treated with monotherapy at the higher dose levels, disease control was observed in 59% (10 of 17 patients) including 9 (53%) patients with stable disease (SD) and one (6%) patient with a partial response (PR). With combination patients included, disease control was observed in 58% (n=14 of 24) including 12 (50%) SD , 1 (4%) PR and 1 (4%) CR. By comparison, in participants with a screening H-score < 50 (low), disease control was 25% (6 of 24 patients) with SD as the best overall response for all patients in the monotherapy cohort. A similar result was observed when including combination patients with 6 of 25 (24%) achieving SD as a best overall response, with none achieving PR or better.
Longer progression free survival was observed in patients with high target expression treated in the 3, 10 and 30 mg/kg dose cohorts. A hazard ratio of 0.47 was observed in a Kaplan Meier analysis of monotherapy patients treated at the higher dose levels separated by H-score (n=41), and a hazard ratio of 0.40 was observed in the Kaplan Meier analysis of combination therapy patients separated by H-score (n=49). The previously reported PR observed in a lung cancer patient and CR observed in a melanoma patient were durable, with a PR extending beyond 300 days and a CR ongoing (418 days as of data cut-off date).
Atreca is continuing to enroll subjects in both the Q3W monotherapy and combination therapy cohorts at the 30 mg/kg dose level, with a focus on the recruitment of H-score high participants across tumor types. Additional data from the ongoing study will inform a future decision concerning whether to advance ATRC-101 into Phase 2 studies and in which indications. Atreca expects to report additional data from the Phase 1b study and provide details on its potential Phase 2 development plans by the end of 2023.
"These results are encouraging and reinforce our belief in the therapeutic potential of ATRC-101. Importantly, they support the relationship we’ve observed between target expression and both ATRC-101’s anti-tumor activity and duration of response," added Dr. Philippe Bishop, Chief Medical Officer of Atreca. "We look forward to providing a development update with go/no-go decisions later this year."

Preclinical Pipeline and Discovery Platform

APN-497444 (‘444) is an Atreca-discovered antibody targeting a novel, tumor-specific glycan. ‘444 displays uniform and tumor-selective binding with high target prevalence in colorectal cancer and exhibits compelling pre-clinical anti-tumor activity and initial safety when weaponized as an ADC. Atreca expects to nominate a clinical candidate from the program in 2023 and is targeting an IND submission in late 2024.
APN-346958 (‘958) is a tumor-selective antibody discovered by Atreca recognizing an RNA-binding protein target. ‘958 exhibits compelling pre-clinical anti-tumor activity and initial safety accompanied by robust immune activation and T cell expansion when weaponized as a T cell bispecific antibody. ‘958 was mutually selected as the first joint program combining an Atreca-discovered antibody with Xencor’s XmAb bispecific Fc domain and a cytotoxic T-cell binding domain (CD3), with Atreca leading preclinical and clinical development. Atreca and Xencor expect to name a candidate from the program in 2023 and target an IND submission by early 2025.
MAM01/ATRC-501 is a novel, Atreca-discovered antibody licensed to the Gates Medical Research Institute ("Gates MRI") for the prevention of malaria. Gates MRI is preparing to file an IND for MAM01/ATRC-501 in 2023. Atreca retains commercial rights in the U.S., Europe and parts of Asia, and potential product development opportunities in those regions include prophylaxis for those traveling to malaria endemic regions.
Pipeline expansion has been accelerated by continued investments in the discovery platform, which have enabled Atreca to generate leads against novel targets more efficiently.
Other Recent Developments and Highlights

In February 2023, Atreca and Xencor, Inc. announced the mutual selection of the first program combining an Atreca-discovered antibody with Xencor’s XmAb bispecific Fc domain and a cytotoxic T-cell binding domain (CD3) under their 2020 strategic collaboration agreement.
In January 2023, Atreca announced the appointment of Philippe Bishop, MD, as Chief Medical Officer.
Fourth Quarter and Full-year 2022 Financial Results

As of December 31, 2022, cash and cash equivalents and investments totaled $70.5 million.
Research and development expenses for the year ended December 31, 2022, were $66.8 million, including non-cash share-based compensation expense of $7.9 million. Research and development expenses for the three months ended December 31, 2022, were $13.8 million, including non-cash share-based compensation expense of $1.3 million.
General and administrative expenses for the year ended December 31, 2022, were $31.5 million, including non-cash share-based compensation expense of $9.0 million. General and administrative expenses for the three months ended December 31, 2022, were $7.5 million, including non-cash share-based compensation expense of $1.9 million.
Atreca reported a net loss of $97.2 million, or basic and diluted net loss per share attributable to common stockholders of $2.52, for the year ended December 31, 2022. The Company reported a net loss of $21.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.55, for the three months ended December 31, 2022.
Conference Call and Webcast Details

Atreca will host a live conference call and webcast, including accompanying slides, today at 4:30 p.m. EDT. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To access the webcast, including accompanying slides, please use this link.

The conference call registration and a live audio webcast and accompanying slide presentation can also be accessed via the Events section of the Company’s investor relations website at View Source An archived replay of the webcast will be available on the Company’s website for 30 days following the live event.